GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Amyris Inc (OTCPK:AMRSQ) » Definitions » ROE %
中文

Amyris (Amyris) ROE %

: 0.00% (As of Mar. 2023)
View and export this data going back to 2010. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Amyris's annualized net income for the quarter that ended in Mar. 2023 was $-773.4 Mil. Amyris's average Total Stockholders Equity over the quarter that ended in Mar. 2023 was $-574.0 Mil. Therefore, Amyris's annualized ROE % for the quarter that ended in Mar. 2023 was N/A%.

The historical rank and industry rank for Amyris's ROE % or its related term are showing as below:

AMRSQ's ROE % is not ranked *
in the Chemicals industry.
Industry Median: 5.42
* Ranked among companies with meaningful ROE % only.

Amyris ROE % Historical Data

The historical data trend for Amyris's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amyris Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -680.66 -

Amyris Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -879.11 - - - -

Competitive Comparison

For the Specialty Chemicals subindustry, Amyris's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amyris ROE % Distribution

For the Chemicals industry and Basic Materials sector, Amyris's ROE % distribution charts can be found below:

* The bar in red indicates where Amyris's ROE % falls into.



Amyris ROE % Calculation

Amyris's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-528.51/( (251.439+-483.689)/ 2 )
=-528.51/-116.125
=N/A %

Amyris's annualized ROE % for the quarter that ended in Mar. 2023 is calculated as

ROE %=Net Income (Q: Mar. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Mar. 2023 ))/ count )
=-773.368/( (-483.689+-664.363)/ 2 )
=-773.368/-574.026
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Amyris  (OTCPK:AMRSQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-773.368/-574.026
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-773.368 / 224.332)*(224.332 / 752.3055)*(752.3055 / -574.026)
=Net Margin %*Asset Turnover*Equity Multiplier
=-344.74 %*0.2982*N/A
=ROA %*Equity Multiplier
=-102.8 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-773.368/-574.026
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-773.368 / -810.544) * (-810.544 / -470.532) * (-470.532 / 224.332) * (224.332 / 752.3055) * (752.3055 / -574.026)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9541 * 1.7226 * -209.75 % * 0.2982 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Amyris ROE % Related Terms

Thank you for viewing the detailed overview of Amyris's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amyris (Amyris) Business Description

Traded in Other Exchanges
N/A
Address
5885 Hollis Street, Suite 100, Emeryville, CA, USA, 94608
Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The business operations are spread across the world with the majority of the revenues generated in the United States. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants, and collaborative research and development services.
Executives
J. Scott White director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip J. Gund officer: Chief Restructuring Officer C/O SUNEDISON, INC., 13736 RIVERPORT DR., MARYLAND HEIGHTS MO 63043
M. Freddie Reiss director 2951 28TH STREET, SUITE 1000, SANTA MONICA CA 90405
Hermanus Kieftenbeld officer: Chief Financial Officer 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Eduardo Alvarez officer: Chief Operating Officer AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
Elizabeth E. Dreyer officer: CHIEF ACCOUNTING OFFICER EDGEWELL PERSONAL CARE, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Frank Kung director C/O VIVO CAPITAL, 505, PALO ALTO CA 94301
Nicole Kelsey officer: General Counsel and Secretary AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
John Melo director, officer: President and CEO C/O AMYRIS, INC., 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Anthony Hughes officer: Chief Accounting Officer 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
Ana Dutra director C/O KORN/FERRY INTERNATIONAL, 1900 AVENUE OF THE STARS, SUITE 2600, LOS ANGELES CA 90067
James F Mccann director ONE OLD COUNTRY ROAD, SUITE 500, CARLE PLACE NY 11514
Ryan Panchadsaram director 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
L John Doerr director, 10 percent owner C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Julie Washington director C/O JAMBA, INC., 6475 CHRISTIE AVENUE, NO. 150, EMERYVILLE CA 94608